A publicly traded, biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases had its primary products fail initial clinical trials.
Public confidence and funding diminished, and the company determined to cease operations.
As Chief Liquidating Officer, addressed and solved remaining wind-down issues such as timely payment severance, financial reporting, collections, lease termination and related wind-down issues, including regulatory and archival issues connected to the failed clinical trials.
The wind-down was successfully transitioned in all financial reporting and related respects.
The company was successfully de-listed, and all required regulatory reports prepared and filed.
Issues of clinical trial regulatory compliance with other notable pharma companies was addressed and resolved.